159 related articles for article (PubMed ID: 38216444)
41. Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study.
Schmidinger M; Motzer RJ; Rolland F; Staehler M; Rink M; Retz M; Csoszi T; McCaffrey JA; De Giorgi U; Caserta C; Duran I; Benzaghou F; Clary DO; Albiges L; Choueiri TK; Tannir NM
Acta Oncol; 2022 Jan; 61(1):52-57. PubMed ID: 34736367
[TBL] [Abstract][Full Text] [Related]
42. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.
Motzer RJ; Hutson TE; Glen H; Michaelson MD; Molina A; Eisen T; Jassem J; Zolnierek J; Maroto JP; Mellado B; Melichar B; Tomasek J; Kremer A; Kim HJ; Wood K; Dutcus C; Larkin J
Lancet Oncol; 2015 Nov; 16(15):1473-1482. PubMed ID: 26482279
[TBL] [Abstract][Full Text] [Related]
43. Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial.
Denize T; Farah S; Cimadamore A; Flaifel A; Walton E; Sticco-Ivins MA; Labaki C; Braun DA; Sun M; Wang E; Xie W; Choueiri TK; Signoretti S
Clin Cancer Res; 2022 Feb; 28(4):748-755. PubMed ID: 34921022
[TBL] [Abstract][Full Text] [Related]
44. Activity of Systemic Treatments After Cabozantinib Failure in Advanced Metastatic Renal Cell Carcinoma.
Cerbone L; Nunno VD; Carril Ajuria L; Alves Costa Silva C; Colomba E; Guida A; Salviat F; Hirsch L; Benchimol-Zouari A; Flippot R; Escudier B; Albiges L
Clin Genitourin Cancer; 2022 Feb; 20(1):80-87. PubMed ID: 34688544
[TBL] [Abstract][Full Text] [Related]
45. Cabozantinib for the treatment of renal cell carcinoma.
Escudier B; Lougheed JC; Albiges L
Expert Opin Pharmacother; 2016 Dec; 17(18):2499-2504. PubMed ID: 27835047
[TBL] [Abstract][Full Text] [Related]
46. Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Stukalin I; Wells JC; Graham J; Yuasa T; Beuselinck B; Kollmansberger C; Ernst DS; Agarwal N; Le T; Donskov F; Hansen AR; Bjarnason GA; Srinivas S; Wood LA; Alva AS; Kanesvaran R; Fu SYF; Davis ID; Choueiri TK; Heng DYC
Curr Oncol; 2019 Apr; 26(2):e175-e179. PubMed ID: 31043824
[TBL] [Abstract][Full Text] [Related]
47. Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.
Powles T; Choueiri TK; Motzer RJ; Jonasch E; Pal S; Tannir NM; Signoretti S; Kaldate R; Scheffold C; Wang E; Aftab DT; Escudier B; George DJ
BMC Cancer; 2021 Aug; 21(1):904. PubMed ID: 34364385
[TBL] [Abstract][Full Text] [Related]
48. Real-World Treatment with Nivolumab or Cabozantinib for Metastatic Renal Cell Carcinoma (mRCC) in the Veneto Region of Italy: Results of AMOUR Study.
Maruzzo M; Pierantoni F; Bortolami A; Palleschi D; Zivi A; Nicodemo M; Sartori D; De Vivo R; Zustovich F; Bimbatti D; Pastorelli D; Vultaggio GD; Soraru' M; Ballestrin M; Modonesi C; Randisi P; Barile C; Perri G; Basso U; Zagonel V
Target Oncol; 2022 Jul; 17(4):467-474. PubMed ID: 35751733
[TBL] [Abstract][Full Text] [Related]
49. Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials.
Han Y; Zhi WH; Xu F; Zhang CB; Huang XQ; Luo JF
World J Gastroenterol; 2021 May; 27(19):2415-2433. PubMed ID: 34040331
[TBL] [Abstract][Full Text] [Related]
50. Cabozantinib and nivolumab as first-line treatment in advanced renal cell carcinoma.
Vitale MG; Nasso C; Oltrecolli M; Baldessari C; Fanelli M; Dominici M; Sabbatini R
Expert Rev Anticancer Ther; 2021 Nov; 21(11):1183-1192. PubMed ID: 34424125
[TBL] [Abstract][Full Text] [Related]
51. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
52. The Optimal Second-Line Systemic Treatment Model for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: A Bayesian Network Meta-Analysis.
Zhan ZJ; Yao WY; Zhang F; Qiu WZ; Liao K; Feng JH; Tan JY; Liu H; Yuan TZ; Zheng RH; Yuan YW
Front Immunol; 2021; 12():719650. PubMed ID: 34413862
[TBL] [Abstract][Full Text] [Related]
53. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
Calvo E; Schmidinger M; Heng DY; Grünwald V; Escudier B
Cancer Treat Rev; 2016 Nov; 50():109-117. PubMed ID: 27664394
[TBL] [Abstract][Full Text] [Related]
54. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
55. Recommendations on managing lenvatinib and everolimus in patients with advanced or metastatic renal cell carcinoma.
Grande E; Glen H; Aller J; Argenziano G; Lamas MJ; Ruszniewski P; Zamorano JL; Edmonds K; Sarker S; Staehler M; Larkin J
Expert Opin Drug Saf; 2017 Dec; 16(12):1413-1426. PubMed ID: 28920492
[TBL] [Abstract][Full Text] [Related]
56. Real-World Results of Cabozantinib Given as Alternative Schedule in Metastatic Renal Cell Carcinoma.
Bruchbacher A; Franke J; Alimohammadi A; Laukhtina E; Fajkovic H; Schmidinger M
Clin Genitourin Cancer; 2024 Apr; 22(2):98-108. PubMed ID: 37926597
[TBL] [Abstract][Full Text] [Related]
57. Treating metastatic clear-cell renal cell carcinoma: beyond immunotherapy.
Perego G; Barzaghi P; Vavassori I; Petrelli F
Med Oncol; 2020 Aug; 37(9):81. PubMed ID: 32767163
[TBL] [Abstract][Full Text] [Related]
58. Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis.
Sonbol MB; Riaz IB; Naqvi SAA; Almquist DR; Mina S; Almasri J; Shah S; Almader-Douglas D; Uson Junior PLS; Mahipal A; Ma WW; Jin Z; Mody K; Starr J; Borad MJ; Ahn DH; Murad MH; Bekaii-Saab T
JAMA Oncol; 2020 Dec; 6(12):e204930. PubMed ID: 33090186
[TBL] [Abstract][Full Text] [Related]
59. Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data.
Ferté C; Koscielny S; Albiges L; Rocher L; Soria JC; Iacovelli R; Loriot Y; Fizazi K; Escudier B
Eur Urol; 2014 Apr; 65(4):713-20. PubMed ID: 23993162
[TBL] [Abstract][Full Text] [Related]
60. CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma.
Escudier B; Sharma P; McDermott DF; George S; Hammers HJ; Srinivas S; Tykodi SS; Sosman JA; Procopio G; Plimack ER; Castellano D; Gurney H; Donskov F; Peltola K; Wagstaff J; Gauler TC; Ueda T; Zhao H; Waxman IM; Motzer RJ;
Eur Urol; 2017 Dec; 72(6):962-971. PubMed ID: 28262413
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
